Introduction of the anti-CD20 monoclonal antibody rituximab in 1997 substantially improved prognosis after a diagnosis of diffuse large B-cell lymphoma (DLBCL),¹ which affects > 27,000 individuals in the United States annually.² With the 5-year relative survival increasing from 43% in the early 1990s to > 65% since 2010 (Fig 1),³ attention has increasingly turned toward improving understanding of patients’ long-term health after DLBCL.

中文翻译：

---

对弥漫性大 B 细胞淋巴瘤幸存者长期免疫健康的新见解。


1997 年推出的抗 CD20 单克隆抗体利妥昔单抗显着改善了诊断为弥漫性大 B 细胞淋巴瘤 (DLBCL) 后的预后， ¹该病每年影响美国超过 27,000 人。 ² 5 年相对生存率从 1990 年代初期的 43% 增加到 2010 年以来的 > 65%（图 1 )， ³人们的注意力越来越多地转向提高对 DLBCL 后患者长期健康状况的了解。